IL228984A0 - Preparations and methods for stabilization of active agents - Google Patents

Preparations and methods for stabilization of active agents

Info

Publication number
IL228984A0
IL228984A0 IL228984A IL22898413A IL228984A0 IL 228984 A0 IL228984 A0 IL 228984A0 IL 228984 A IL228984 A IL 228984A IL 22898413 A IL22898413 A IL 22898413A IL 228984 A0 IL228984 A0 IL 228984A0
Authority
IL
Israel
Prior art keywords
stabilization
compositions
methods
active agents
agents
Prior art date
Application number
IL228984A
Other languages
English (en)
Hebrew (he)
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Publication of IL228984A0 publication Critical patent/IL228984A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/20—Rubella virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0015—Combination vaccines based on measles-mumps-rubella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
IL228984A 2011-04-21 2013-10-21 Preparations and methods for stabilization of active agents IL228984A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477737P 2011-04-21 2011-04-21
PCT/US2012/034643 WO2012145739A1 (en) 2011-04-21 2012-04-23 Compositions and methods for stabilization of active agents

Publications (1)

Publication Number Publication Date
IL228984A0 true IL228984A0 (en) 2013-12-31

Family

ID=47041958

Family Applications (1)

Application Number Title Priority Date Filing Date
IL228984A IL228984A0 (en) 2011-04-21 2013-10-21 Preparations and methods for stabilization of active agents

Country Status (9)

Country Link
US (3) US20140287043A1 (enExample)
EP (1) EP2699266B1 (enExample)
JP (2) JP6170906B2 (enExample)
CN (2) CN105148285B (enExample)
AU (6) AU2012245198B2 (enExample)
BR (1) BR112013027057A2 (enExample)
CA (1) CA2833879C (enExample)
IL (1) IL228984A0 (enExample)
WO (1) WO2012145739A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102271724B (zh) 2008-10-09 2015-10-14 塔夫茨大学信托人 含有甘油的改性丝膜
US20140287043A1 (en) 2011-04-21 2014-09-25 Trustees Of Tufts College Compositions and methods for stabilization of active agents
WO2013106822A1 (en) 2012-01-12 2013-07-18 Johnson Jed K Nanofiber scaffolds for biological structures
JP2015510818A (ja) 2012-03-20 2015-04-13 トラスティーズ オブ タフツ カレッジ 薬物送達のための絹リザーバー
WO2013155404A1 (en) 2012-04-13 2013-10-17 Trustees Of Tufts College Methods and compositions for preparing a silk microsphere
US10653786B2 (en) 2012-04-25 2020-05-19 Trustees Of Tufts College Silk microspheres and methods for surface lubrication
WO2014127309A1 (en) 2013-02-15 2014-08-21 Tufts University Silk-based nanoimprinting
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
WO2014197093A2 (en) 2013-03-15 2014-12-11 Tufts University All water-based nanopatterning
AU2014233480B2 (en) * 2013-03-15 2018-08-09 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
AU2014240170B2 (en) * 2013-03-15 2018-05-17 Patheon Softgels Inc. Silk-based capsules
WO2014144971A1 (en) 2013-03-15 2014-09-18 Tufts University Silk water lithography
ITMI20131255A1 (it) * 2013-07-26 2015-01-27 Ct Tessile Serico Societa Co Nsortile Per A Composizioni farmaceutiche nebulizzabili a base di fibroina per il trattamento di lesioni cutanee
CN105579059B (zh) * 2013-09-03 2020-07-31 佐治亚科技研究公司 热稳定的疫苗配制物、工艺和包含疫苗配制物的微针
CA2923753C (en) 2013-09-19 2021-10-12 Terumo Corporation Polymer particles
BR112016005768B1 (pt) * 2013-09-19 2021-09-21 Microvention, Inc Películas de polímero
KR20210153142A (ko) * 2013-09-30 2021-12-16 실크 테라퓨틱스, 인코퍼레이티드 실크 단백질 단편 조성물 및 이로부터 제작된 물품
EP3065719A4 (en) 2013-11-08 2017-08-09 Terumo Corporation Polymer particles
ES2875330T3 (es) * 2014-04-04 2021-11-10 Nanofiber Solutions Llc Composiciones de fibras biocompatibles electrohiladas
EA035551B1 (ru) 2014-12-02 2020-07-06 Силк Терапьютикс, Инк. Изделие
US10213378B2 (en) * 2015-03-10 2019-02-26 Sporos Therapeutics, LLC Single dose non-adjuvanted cutaneous tetanus vaccine and uses thereof
US9907880B2 (en) 2015-03-26 2018-03-06 Microvention, Inc. Particles
CN104940981B (zh) * 2015-05-21 2018-11-30 重庆市畜牧科学院 具有生物活性的外用敷料及其制备方法
CN108135975A (zh) 2015-07-14 2018-06-08 丝绸医疗公司 丝性能服装和产品及其制备方法
CN105903027A (zh) * 2016-05-31 2016-08-31 福建傲农生物科技集团股份有限公司 一种常温下长期保存抗生素的方法
WO2017214187A1 (en) * 2016-06-07 2017-12-14 Aridis Pharmaceuticals, Inc. Method for preparation of quick dissolving thin films containing bioactive material with enhanced thermal stability
CN106362223B (zh) * 2016-08-26 2019-05-03 南通纺织丝绸产业技术研究院 多孔丝素蛋白微针给药装置及其制备方法
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US20190275136A1 (en) * 2016-09-19 2019-09-12 Vaxess Technologies, Inc. Vaccine formulations with increased stability
CA3038642C (en) 2016-09-28 2021-11-02 Terumo Corporation Polymer particles comprising polymerizable pharmaceutical agents
US10857262B2 (en) 2016-10-31 2020-12-08 Sofregen Medical, Inc. Compositions comprising low molecular weight silk fibroin fragments and plasticizers
US10898608B2 (en) 2017-02-02 2021-01-26 Nanofiber Solutions, Llc Methods of improving bone-soft tissue healing using electrospun fibers
US11390988B2 (en) 2017-09-27 2022-07-19 Evolved By Nature, Inc. Silk coated fabrics and products and methods of preparing the same
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
SG11202007503WA (en) * 2018-02-07 2020-09-29 Bharat Biotech Int Ltd A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
EP3830576A2 (en) * 2018-07-27 2021-06-09 Vaxess Technologies, Inc. Polymer-based biospecimen collection devices and uses thereof
CA3111273C (en) * 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
MX2021006436A (es) 2018-12-10 2021-09-14 Cambridge Crops Inc Composiciones y metodos para la extension de la vida util a base de polimero.
TWI691531B (zh) * 2019-02-11 2020-04-21 南臺學校財團法人南臺科技大學 蠶絲蛋白膜的製造方法
AU2020288624B2 (en) 2019-06-04 2025-09-25 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
CN110627899A (zh) * 2019-10-09 2019-12-31 山东天牧生物科技有限公司 一种呼肠孤病毒和细小病毒卵黄抗体锭及其制备方法
WO2021076798A1 (en) 2019-10-15 2021-04-22 Sofregen Medical, Inc. Delivery devices for delivering and methods of delivering compositions
US20220409484A1 (en) * 2019-11-18 2022-12-29 Elanco Us Inc. Lyophilized cake in straight-walled vial
US20230285536A1 (en) * 2020-06-24 2023-09-14 Trustees Of Tufts College Edible cell based vaccines
WO2022101877A1 (pt) * 2020-11-13 2022-05-19 Targetalent, Lda Composição de criopreservação de amostras biológicas para pcr
WO2022109294A2 (en) * 2020-11-20 2022-05-27 Team Medical Llc Rna stabilization
US20240117321A1 (en) * 2021-03-02 2024-04-11 Georgia Tech Research Corporation Hydrogel materials and methods of making and transport using the same
US11976196B2 (en) 2021-04-14 2024-05-07 Cambridge Crops, Inc. Silk packaging applications
US11584784B2 (en) 2021-05-21 2023-02-21 Cambridge Crops, Inc. Systems and methods for manufacturing a silk fibroin solution and powders containing silk fibroin
US11864569B2 (en) 2021-08-16 2024-01-09 Cambridge Crops, Inc. Systems and methods for improving the performance of cereal using a silk fibroin solution and powders containing silk fibroin
CN116421734A (zh) * 2021-12-30 2023-07-14 深圳复诺健生物科技有限公司 适用于溶瘤病毒的冻干保护剂及其应用
US20250223571A1 (en) 2022-03-30 2025-07-10 Bioneedle Drug Delivery B.V. A process for storing biologically active constructs in a biodegradable material
CN115227863A (zh) * 2022-07-01 2022-10-25 浙江大学 一种搭载噬菌体的复合水凝胶及其制备方法
EP4613287A1 (en) * 2022-10-31 2025-09-10 National Agriculture And Food Research Organization Oral-administration-type vaccine composition containing fibroin-containing nanoparticles

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8808A (en) 1852-03-16 Planiwg-machiete
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
JPH0652268B2 (ja) * 1985-07-03 1994-07-06 鐘紡株式会社 固定化抗原
CN86100565A (zh) * 1986-04-30 1987-11-11 华东化工学院 一种共价活化的固定化酶载体
JPH07121871B2 (ja) * 1986-10-09 1995-12-25 国立予防衛生研究所長 インフルエンザワクチン凍結乾燥製剤
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
IE61575B1 (en) 1987-05-04 1994-11-16 Merck & Co Inc A stable lyophilized live herpes virus vaccine
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2750306B2 (ja) * 1989-05-24 1998-05-13 ポーラ化成工業株式会社 固定化低分子プロテインａの製造法
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5245012A (en) 1990-04-19 1993-09-14 The United States Of America As Represented By The Secretary Of The Army Method to achieve solubilization of spider silk proteins
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5346481A (en) 1993-10-14 1994-09-13 Merck & Co., Inc. Vaccine delivery system
US5900238A (en) 1995-07-27 1999-05-04 Immunex Corporation Vaccine delivery system
IL123398A0 (en) 1995-08-22 1998-09-24 Agricola Tech Inc Cloning methods for high strength spider silk proteins
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
AU725231B2 (en) 1996-12-20 2000-10-12 Merck & Co., Inc. Stabilisers for lyophilised vaccines
JP3101711B2 (ja) * 1997-11-20 2000-10-23 農林水産省蚕糸・昆虫農業技術研究所長 生体高分子からなる吸着体／徐放体及びその製造方法
WO2001012157A1 (en) 1999-08-18 2001-02-22 Microchips, Inc. Thermally-activated microchip chemical delivery devices
EP1690527B1 (en) 1999-11-17 2015-01-07 Boston Scientific Limited Microfabricated devices for the delivery of molecules into a carrier fluid
EP1372602B1 (en) 2001-01-09 2007-04-18 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US20020193729A1 (en) 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
RU21271U1 (ru) * 2001-08-06 2002-01-10 Алкацева Надежда Ильинична Основа для косметических средств
AR040819A1 (es) 2002-08-08 2005-04-20 Alza Corp Dispositivo de administracion transdermica de vacuna que tiene microproyecciones revestidas
JP2005097229A (ja) * 2002-12-04 2005-04-14 Toray Ind Inc ワクチンおよび抗原タンパク質の製造方法
WO2004062697A2 (en) 2003-01-07 2004-07-29 Tufts University Silk fibroin materials and use thereof
US7060260B2 (en) * 2003-02-20 2006-06-13 E.I. Du Pont De Nemours And Company Water-soluble silk proteins in compositions for skin care, hair care or hair coloring
EP1613796B1 (en) 2003-04-10 2017-03-22 Tufts University Concentrated aqueous silk fibroin solution and use thereof
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123565A1 (en) 2003-10-31 2005-06-09 Janardhanan Subramony System and method for transdermal vaccine delivery
JP2007518468A (ja) 2003-11-21 2007-07-12 アルザ・コーポレーシヨン 超音波支援経皮ワクチン送達方法およびシステム
CN1243059C (zh) * 2004-03-04 2006-02-22 苏州大学 纳米丝素颗粒的制造方法
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US7960509B2 (en) 2005-01-14 2011-06-14 Trustees Of Tufts College Fibrous protein fusions and use thereof in the formation of advanced organic/inorganic composite materials
CA2645934C (en) * 2005-08-02 2014-04-29 Trustees Of Tufts College Methods for stepwise deposition of silk fibroin coatings
US20090182306A1 (en) * 2006-07-21 2009-07-16 Georgia Tech Research Corporation Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal
US20100028451A1 (en) 2006-09-26 2010-02-04 Trustees Of Tufts College Silk microspheres for encapsulation and controlled release
CA2704768A1 (en) * 2006-11-03 2008-10-23 Trustees Of Tufts College Biopolymer sensor and method of manufacturing the same
WO2008127401A2 (en) 2006-11-03 2008-10-23 Trustees Of Tufts College Biopolymer optical waveguide and method of manufacturing the same
DK2211876T3 (en) 2007-05-29 2015-01-12 Tufts College PROCESS FOR silk fibroin-GELATION USING sonication
WO2009048607A1 (en) * 2007-10-10 2009-04-16 Corium International, Inc. Vaccine delivery via microneedle arrays
CN101925675A (zh) * 2007-11-28 2010-12-22 器官发生有限公司 生物工程化组织构建物及其制备和使用方法
US8206774B2 (en) 2008-03-13 2012-06-26 Trustees Of Tufts College Diazonium salt modification of silk polymer
US8501172B2 (en) 2008-09-26 2013-08-06 Trustees Of Tufts College pH-induced silk gels and uses thereof
CN102271724B (zh) 2008-10-09 2015-10-14 塔夫茨大学信托人 含有甘油的改性丝膜
WO2010057142A2 (en) 2008-11-17 2010-05-20 Trustees Of Tufts College Surface modification of silk fibroin matrices with poly(ethylene glycol) useful as anti adhesion barriers and anti thrombotic materials
CA2791580C (en) 2009-03-04 2017-12-05 Trustees Of Tufts College Silk fibroin systems for antibiotic delivery
WO2011005381A2 (en) 2009-06-01 2011-01-13 Trustees Of Tufts College Vortex-induced silk fibroin gelation for encapsulation and delivery
US8293486B2 (en) 2009-07-21 2012-10-23 Trustees Of Tufts College Functionalization of silk material by avidin-biotin interaction
EP2483199B1 (en) 2009-09-29 2017-04-26 Trustees Of Tufts College Silk nanospheres and microspheres and methods of making same
AU2011317107B2 (en) * 2010-10-19 2016-02-25 Trustees Of Tufts College Silk fibroin-based microneedles and methods of making the same
CN102085173B (zh) * 2011-01-26 2012-05-30 上海交通大学 以天然蚕丝蛋白为乳化剂的生物活性乳液及其制备方法
US20140287043A1 (en) 2011-04-21 2014-09-25 Trustees Of Tufts College Compositions and methods for stabilization of active agents

Also Published As

Publication number Publication date
AU2020217419A1 (en) 2020-09-17
CA2833879C (en) 2023-03-14
US20180360947A1 (en) 2018-12-20
EP2699266B1 (en) 2019-06-12
AU2018226377A1 (en) 2018-09-27
US20170258889A1 (en) 2017-09-14
AU2017204162A1 (en) 2017-07-27
BR112013027057A2 (pt) 2020-08-11
JP2014518557A (ja) 2014-07-31
AU2022235540A1 (en) 2022-10-20
EP2699266A1 (en) 2014-02-26
US12280101B2 (en) 2025-04-22
AU2018226377B2 (en) 2020-09-03
CA2833879A1 (en) 2012-10-26
WO2012145739A1 (en) 2012-10-26
CN105148285B (zh) 2019-02-12
US20140287043A1 (en) 2014-09-25
AU2012245198B2 (en) 2017-07-13
CN105148285A (zh) 2015-12-16
AU2012245198A1 (en) 2013-11-07
JP6170906B2 (ja) 2017-07-26
AU2020203212A1 (en) 2020-06-11
EP2699266A4 (en) 2014-12-24
CN103796683A (zh) 2014-05-14
JP2017137328A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
IL228984A0 (en) Preparations and methods for stabilization of active agents
IL277027A (en) Methods and preparations for regulating transgene expression
IL263729A (en) Preparations and methods for removing biofilms
EP2721019A4 (en) THERAPEUTIC ACTIVE COMPOSITIONS AND METHOD FOR THEIR USE
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
LT2640370T (lt) Kompozicijos, skirtos aktyvių agentų įvedimui po oda
PT2776567T (pt) Composições e métodos para o tratamento de citomegalovírus
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
IL227333A0 (en) A method for preparing lycosphingolipids and their uses
SG10202009963PA (en) Melanin modification compositions and methods of use
PH12013501969A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
GB201411462D0 (en) Prebiotic formulations and methods of use
IL242545B (en) Compositions and methods for administering hydrophobic active substances
IL228205B (en) Compositions and methods for treatment of intracellular damage
IL227924A0 (en) Preparations and methods of use for determining a4he
EP2670243A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLAUCOMA
IL250307A0 (en) Pesticide preparations and methods
ZA201306643B (en) Formulation comprising phenylaminopyrimidine derivatives as active agent
EP2768481A4 (en) COMPOSITIONS TO REDUCE SIDE EFFECTS
PL2736328T3 (pl) Biocydowe kompozycje oraz sposoby stosowania
IL226237B (en) Pharmaceutical preparations for administration of active substances through the skin
IL233284A0 (en) Compounds and methods for improving the stability and extending the shelf life of flavoring materials
PL2736339T3 (pl) Biocydowe kompozycje oraz sposoby stosowania
PL394278A1 (pl) Sposób ograniczania termo genezy torfu